Peripheral Artery Disease - Medical Therapy and Supervised Exercise

Key Points

• PAD is a systemic atherosclerotic disease, not only a leg-symptom disorder.
• Resting ABI is the key initial diagnostic test in most patients.
• High-intensity statin therapy is recommended for PAD.
• Symptomatic PAD generally requires antiplatelet therapy.
• Low-dose rivaroxaban 2.5 mg twice daily plus low-dose aspirin reduces cardiovascular and limb events in selected low-bleeding-risk patients.
• Structured exercise is a core first-line claudication treatment.
• Cilostazol can improve walking distance but should not be used in heart failure.
• Chronic limb-threatening ischemia requires revascularization evaluation to prevent limb loss.

Algorithm

1. Assess leg symptoms, pulses, wounds, rest pain and signs of acute or chronic limb threat.
2. Obtain resting ABI; use toe pressures or exercise testing when ABI is noncompressible or symptoms remain unexplained.
3. Start high-intensity statin, antiplatelet therapy and aggressive smoking/BP/diabetes management.
4. Consider low-dose rivaroxaban plus aspirin if symptomatic and bleeding risk is acceptable.
5. Refer claudication patients to supervised or structured exercise therapy.
6. Use cilostazol selectively when symptoms persist and heart failure is absent.
7. Refer chronic limb-threatening ischemia urgently for revascularization and wound/foot care.
8. Continue longitudinal surveillance for cardiovascular events, limb symptoms, wounds, medication adherence and functional status.

Clinical Synopsis & Reasoning

PAD can present as exertional calf, thigh, or buttock discomfort relieved by rest, but many patients have atypical leg symptoms or no classic claudication. Examination should include femoral/popliteal/pedal pulses, skin temperature and color, capillary refill, hair/skin changes, wounds, gangrene, and foot deformity. Rest pain, nonhealing ulceration, or gangrene suggests chronic limb-threatening ischemia and requires urgent vascular referral. Sudden pain, pallor, pulselessness, paresthesia, paralysis, or poikilothermia suggests acute limb ischemia and follows an emergency revascularization pathway rather than routine outpatient PAD care.

Resting ankle-brachial index is the standard initial diagnostic test in most symptomatic patients. ABI <=0.90 supports PAD; values >1.40 can indicate noncompressible calcified arteries, especially in diabetes or CKD, and toe-brachial index or vascular imaging may be needed. Exercise ABI can uncover disease when resting values are normal but exertional symptoms are classic. Duplex ultrasound, CTA or MRA maps anatomy when revascularization is considered. PAD is a marker of diffuse atherosclerosis, so treatment aims to prevent both limb events and heart attack/stroke.

Treatment Strategy & Disposition

The 2024 AHA/ACC guideline recommends high-intensity statin therapy for PAD and aggressive treatment of hypertension, diabetes and tobacco use. Symptomatic PAD generally warrants single antiplatelet therapy with aspirin or clopidogrel. In patients without increased bleeding risk, low-dose rivaroxaban 2.5 mg twice daily combined with low-dose aspirin is effective for reducing major adverse cardiovascular and limb events, including after lower-extremity revascularization. Full-dose anticoagulation is not used solely for stable PAD unless there is another indication such as atrial fibrillation or VTE.

Structured exercise is a core therapy for claudication and includes supervised exercise therapy or a structured community/home program when supervised care is unavailable. Walking to moderate-to-severe claudication discomfort followed by rest, repeated over sessions, improves walking distance and quality of life. Cilostazol can improve claudication walking distance but is contraindicated in heart failure. Revascularization is indicated to prevent limb loss in chronic limb-threatening ischemia and can improve quality of life when lifestyle-limiting claudication persists despite guideline-directed medical therapy and structured exercise. Preventive foot care is essential, particularly with diabetes and neuropathy.

Epidemiology / Risk Factors

• PAD affects millions of adults and prevalence rises with age, smoking, diabetes, CKD and established atherosclerosis.
• Many patients have atypical symptoms rather than textbook intermittent claudication.
• PAD substantially increases risk of myocardial infarction, stroke and cardiovascular death.
• Diabetes and smoking increase the risk of chronic limb-threatening ischemia and amputation.

Investigations

Core Measures

Pharmacology

Prognosis / Complications

• Guideline-directed medical therapy reduces cardiovascular events and can slow limb progression.
• Structured exercise often produces large improvements in walking distance without a procedure.
• Chronic limb-threatening ischemia has high amputation and mortality risk without timely revascularization and wound care.
• Continued smoking markedly worsens graft, stent, limb and cardiovascular outcomes.

Patient Education / Counseling

• Explain that PAD treatment protects the heart and brain as well as the legs.
• Encourage a structured walking program rather than avoiding activity because claudication occurs.
• Inspect feet daily for blisters, color change, cracks or wounds, especially with diabetes or neuropathy.
• Seek urgent care for sudden severe limb pain, coldness, numbness or weakness.
• Review bleeding precautions when rivaroxaban plus aspirin is used and avoid unnecessary NSAIDs.

Notes

The 2024 AHA/ACC PAD guideline treats exercise as a prescription, not optional lifestyle advice. Supervised exercise therapy is underused despite strong evidence and insurance coverage in many settings. Revascularization for claudication should generally follow an adequate trial of guideline-directed medical therapy and structured exercise unless anatomy or symptoms create a different urgent indication.

Low-dose rivaroxaban plus aspirin is “dual pathway inhibition,” not full-intensity anticoagulation. It lowers vascular and limb events but increases bleeding, so it is selected for patients in whom the ischemic benefit outweighs bleeding risk. It should not be confused with standard-dose rivaroxaban used for atrial fibrillation or VTE.

References

1. 2024 AHA/ACC Guideline for Management of Lower Extremity Peripheral Artery Disease — Link